Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Body’s response to injury and inflammation may hinder wound healing in diabetes

BOSTON, June 15, 2015 /PRNewswire-USNewswire/ — One of the body’s own tools for preventing wound infections may actually interfere with wound healing, according to new research from Boston Children’s Hospital. In a study published online in Nature Medicine, scientists from the hospital’s Program in Cellular and Molecular Medicine (PCMM) found they could speed up wound healing […]

Read More »

Johnson & Johnson Strikes 17 New Pacts to Battle Diabetes, Other Diseases

Johnson & Johnson Innovation Announces 17 Collaborations With Focus on Advancing Global Healthcare Through Transformational Science and Technologies NEW BRUNSWICK, N.J., June 11, 2015 /PRNewswire/ — Johnson & Johnson Innovation today announced 17 new collaborations with research institutions and healthcare companies, bringing the total number of collaborations formed since the 2013 launch of Johnson & Johnson […]

Read More »

Bayer Dumps Diabetes Care Biz for $1.15 Billion

German pharma giant Bayer AG (BAYZF) will sell its diabetes business to Panasonic’s healthcare unit for around $1.15 billion, as the company begins shedding nonessential assets as part of a mission to refocus on life sciences. The deal will close in the first quarter of 2016, said the companies. The products included in the sale […]

Read More »

Giant Study Boosts Januvia, Merck’s $6 Billion Drug

Januvia, a widely used diabetes drug that generates $6 billion in annual sales for maker Merck, does not increase patients’ risk of being hospitalized for heart failure, a risk that did show up in clinical trials of competing drugs. “We’ve teased this data backwards and forwards and everything comes up looking like the drug does […]

Read More »

GLP-1 Alters How the Brain Responds to Food

BOSTON, June 9, 2015 /PRNewswire-USNewswire/ — Gut hormone-based medications used to treat diabetes, such as GLP-1 receptor agonists, have also been shown to reduce body weight. Researchers have been working to understand how. This study, presented today at the American Diabetes Association’s 75th Scientific Sessions, sheds light on how GLP-1 receptor agonists alter the brain’s response […]

Read More »

FDA approves mid-stage trial of vaccine to reverse type 1 diabetes

Diabetes researchers are hoping that an almost century-old vaccine for preventing tuberculosis may also reverse type 1 diabetes. The FDA has approved a mid-stage trial to test the vaccine, called bacillus Calmette-Guerin (BCG), in 150 adults with advanced cases of the disease. The approval was announced Sunday at the 75th Scientific Sessions of the American […]

Read More »

Here’s How Lee Iacocca Wants To Cure Diabetes

In the late 1990s, former Chrysler CEO Lee Iacocca handed more than $10 million to Massachusetts General Hospital (MGH) scientist Denise Faustman and instructed her to transform an ancient tuberculosis vaccine into a cure for type 1 diabetes. Today Faustman announced the latest milestone in that project—FDA clearance to launch a large trial in people […]

Read More »

Hanmi Pharmaceutical : Once-Weekly Insulin Combination, ‘LAPSInsulin Combo’, Suggests a New Diabetes Therapeutic Option

SEOUL, South Korea–(BUSINESS WIRE)–Hanmi Pharmaceutical Co., Ltd.(KSE: 128940) made an oral presentation on the non-clinical results of once weekly insulin and GLP-1 combination drug ‘LAPSInsulin Combo’ at the 75th American Diabetes Association (ADA) Scientific Session on June 7 in the Boston Convention Center, USA. Hanmi Pharmaceutical presented the possibility of developing a new insulin combination […]

Read More »

New IDegLira Phase 3b Study Showed Statistically Significant HbA1c Reduction, Body Weight Change, and Lower Rate of Hypoglycaemia Versus Insulin Glargine

BOSTON, June 7, 2015 /PRNewswire/ — – 166-OR For medical and consumer media in the US only  New phase 3b findings showed adults with type 2 diabetes treated with IDegLira, the investigational once-daily, single-injection combination of insulin degludec and liraglutide in the United States, demonstrated statistically significant reduction in HbA1c (average blood glucose over the […]

Read More »

50 Years of Diabetes Research and Treatment

BOSTON, June 6, 2015 /PRNewswire-USNewswire/ — From how people test their glucose levels to how long they can expect to live, almost everything has changed over the past 50 years for Americans with diabetes. A special symposium held at the American Diabetes Association’s 75th Scientific Sessions features a look back at what physicians and researchers […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom